EGFR and cancer: Lung cancer is one of the leading causes of cancer‐related death.1 Non‐small cell lung cancer (NSCLC) accounts for more than 80% lung cancer cases, where adenocarcinoma is the most common histological subtype.2 With the advancements of genomics, several genomic alternations, such as oncogenic ALK rearrangements,3ROS1 rearrangement,4KRAS mutations,5 and sensitizing EGFR mutations,6 have been identified as predictive and prognostic markers for NSCLC.